This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ARTHUR G. SCHOCH, M.D.; LEE J. ALEXANDER, M.D.; W. E. LONG, M.D.

Arch Derm Syphilol. 1940;42(5):919-932.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Our primary objective several years ago in starting this study was to evaluate the usefulness of a new drug of low toxicity, mapharsen, for patients who had recovered from arsphenamine dermatitis of varying grades of severity. Moore and Keidel¹ were the first to describe the procedure of intravenous testing. It is open to question whether intravenous testing is a desensitization procedure. Intravenous testing with mapharsen offered a new approach to this problem.

Foerster, McIntosh, Wieder, Foerster and Cooper,² in their excellent original article on the clinical use of mapharsen, were the first to report administration of mapharsen to a patient who had recovered from arsphenamine dermatitis. They reported a single incident in which mapharsen was administered to such a patient, one dose being given, with recurrence of the dermatitis. They observed no cases of severe exfoliative dermatitis resulting from the use of mapharsen alone in the original study, . . . [Full Text PDF of this Article]

Author Affiliations
DALLAS, TEXAS

From the department of Dermatology and Syphilology, Baylor Medical College, and the Dallas Syphilis and Venereal Disease Clinic, Parkland Hospital, Arthur G. Schoch, M.D., Director.

Footnotes
Read at the Sixty-Third Annual Meeting of the American Dermatological Association, Inc., Colorado Springs, Colo., May 30, 1940.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?